Assessing long-term maintenance of efficacy with tralokinumab monotherapy in patients with moderate-to-severe atopic dermatitis: combined results from two phase 3, randomized, double-blind, placebo-controlled trials (ECZTRA 1 and 2). J of Skin [Internet]. 2021 Nov. 5 [cited 2025 Apr. 16];5(6):s57. Available from: https://skin.dermsquared.com/skin/article/view/1408